conditioning regimens
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods
Vertex Pharmaceuticals; Enlaza Therapeutics; autoimmune diseases; gene therapy; conditioning regimens; War-Lock platform; covalent biologics; drug conjugates; T-cell engagers; biotech alliance